Blafarm, COVID gave us a head start on all indications. If a vaccine is available by end of 2021, that is fine. I'm sure there will be a shortage in supply for our drug in any indications, including off label usage. We only need an approval or two.

So, our limit after approval is production limit.
NP confirm that be the case by saying we can to $2.5 b revenue I. 2020 and $9 b in 2021. Adding up to $11.5 revenue.

Into 2022 and the following years we shall still be capped by production limit.
All IMO